Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OROS Methylphenidate in Adolescents with ADHD
NCT01060150Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of methylphenidate hydrochloride extended-release chewable tablet in attention deficit hyperactivity disorder (ADHD), sponsored by Janssen Pharmaceutical. Primary endpoints: Korean Version of the ADHD Rating Scale at 12 weeks, Clinical Global Impression - Severity at 12 weeks and 2 more. Started Jul 2008; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01060150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01060150.